From Indonesia to Global Recognition: CUHK Biomedical Engineering Student's Journey of Excellence
Michelle's team achieved distinction at the prestigious iGEM Grand Jamboree 2024 in Paris, securing a Gold Medal for their project "ResiSense" and earning a nomination for Best Education in the Undergraduate category. "Participating in the iGEM Grand Jamboree marked my first European experience. The achievement exceeded our expectations and validated our year-long dedication to the project," Michelle reflects.
Research Portfolio
Michelle's academic journey encompasses significant research experience across multiple disciplines. Her portfolio includes a summer internship with Belun Technology Company Limited at the Hong Kong Science and Technology Park, research in optogenetics under Professor Duan Liting's supervision, and an ongoing research internship in Professor Jonathan Choi's nanomedicine laboratory.
Academic Excellence
The CUHK Biomedical Engineering programme offers a comprehensive curriculum integrating multiple disciplines. "The programme's interdisciplinary approach, combining biological sciences, engineering principles, and hands-on project experience, provides an excellent foundation for innovation in medical technology," notes Michelle, who recently presented her research findings at TEDxCUHK.
Strategic Educational Choice
Michelle selected CUHK based on its academic reputation, comprehensive scholarship programme, and strategic position in Asia. "Hong Kong's unique position as a bridge between Eastern and Western cultures, combined with CUHK's extensive network of industry partnerships and research opportunities, creates an ideal environment for international students," she explains.
Future Trajectory
As she approaches her final year, Michelle is focusing on her Final Year Project while participating in a departmental innovation initiative. Her post-graduation plans include pursuing doctoral studies, building upon her substantial undergraduate research experience.
Programme Impact
Michelle's achievements exemplify CUHK's success in delivering world-class biomedical engineering education that combines rigorous academic training with practical research opportunities. The programme continues to attract high-caliber international students, offering comprehensive development opportunities in Hong Kong's dynamic research and innovation ecosystem.
For detailed information about CUHK's Biomedical Engineering programme, visit: https://www.bme.cuhk.edu.hk/new/index.php
Hashtag: #CUHK
The issuer is solely responsible for the content of this announcement.
About CUHK
Founded in 1963, The Chinese University of Hong Kong (CUHK) stands as a leading comprehensive research university, consistently ranked among Asia's top educational institutions.
The Chinese University of Hong Kong
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
11 hours ago
- The National
Polio vaccination drive targets 1.3m children in government-controlled Yemen
The World Health Organisation has launched a three-day polio vaccination campaign in Yemen, targeting 1.3 million children across 12 provinces under government control. Yemen is at high risk for poliovirus outbreaks due to the civil war, which has weakened the healthcare and water hygiene systems, the WHO has said. 'With poliovirus continuing to circulate and cases confirmed in 2025, these [vaccination] campaigns are essential to interrupt transmission and protect every child from the debilitating effects of polio,' WHO Representative in Yemen Dr Ferima Coulibaly-Zerbo said. More than 280 cases of poliovirus have been recorded in Yemen since 2021, across 19 of the country's 22 provinces. Nearly all the cases have involved children under five years old. The campaign is being run by the WHO, led by the Ministry of Health, with support from Unicef – the UN agency for children - and the Global Polio Eradication Initiative. Nearly 7,000 vaccination teams, including 6,000 going door-to-door and 800 others at health care facilities, are inoculating children. 'The campaign is an important and urgent step to protect children from being paralysed by the poliovirus,' said Unicef's Representative to Yemen, Peter Hawkins. 'With confirmed cases of polio among Yemeni children, an imminent threat persists, especially for every unvaccinated child. But through vaccination we can keep our children safe.' Yemen was polio-free for decades until 2020, but national polio immunisation coverage dropped from 58 per cent in 2022 to 46 per cent in 2023, Unicef said.
Zawya
19 hours ago
- Zawya
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity. The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing. SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy ® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia 1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake 1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity 2 - 4, a condition associated with more than 200 health complications 5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease 6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, "Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity" Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week 7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said "With treatments like Wegovy ® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes." References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from World Obesity. Retrieved from Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at World Health Organization. (2024). Obesity and overweight. As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit Novo Nordisk
Zawya
a day ago
- Zawya
Kaspersky Partners with SIS International Limited to Expand Distribution in Hong Kong
HONG KONG SAR - Media OutReach Newswire - 11 July 2025 - Global cybersecurity and digital privacy company Kaspersky is pleased to expand its distribution network in Hong Kong by partnering with SiS International Limited. This collaboration reinforces Kaspersky's commitment to providing accessible, cutting-edge cybersecurity solutions to businesses and individuals across the region. This strategic collaboration highlights SIS International Limited's dedication to delivering premium IT solutions and supporting the region's digital transformation. Through SiS International Limited, Kaspersky's industry-leading security products —including endpoint protection, threat intelligence, and advanced threat detection and response —will be more widely available, ensuring enhanced protection against evolving cyber threats. "As cyber risks continue to grow, partnering with a trusted distributor like SIS International Limited allows us to strengthen our reach and better serve customers in Hong Kong," Adrian Hia, Managing Director for Asia Pacific. "This expansion ensures that businesses and individuals have seamless access to the cybersecurity tools they need to safeguard their digital environments." General Manager of Kaspersky in Greater China Alvin Cheng said, "We are honored that Kaspersky has signed an agency agreement with SIS International Limited. Currently, with the continuous escalation of cybersecurity challenges, Kaspersky's technologies and products possess significant advantages. By leveraging the resources of SIS International Limited, we are able to provide customized security services to enterprises in various sectors in Hong Kong, China. Through the joint efforts of both parties, we are certain to build a high-quality ecosystem, create more business opportunities, achieve a win-win situation, and drive the development of the industry." "We are deeply honored to be appointed as Kaspersky's official distributor in Hong Kong," said Raymond Au, general manager at SiS International Limited. "This partnership aligns seamlessly with our mission to provide cutting-edge IT solutions and enhance cybersecurity for our valued clients. We are committed to working closely with Kaspersky to deliver advanced security solutions tailored to the unique needs of the Hong Kong market." By joining forces with SIS International Limited, Kaspersky is enhancing product availability, customer support, and cybersecurity resilience across Hong Kong. Clients can expect greater convenience and improved service quality, reinforcing the region's defenses against modern cyber threats. This collaboration comes at a pivotal time when cybersecurity is of paramount importance, as businesses and individuals face increasingly sophisticated cyber threats. By joining forces, Kaspersky and SiS International Limited are committed to fostering a secure digital environment and empowering organizations to thrive in the digital era. For more information, please contact: Joe Lam, channel director, Kaspersky Hong Kong Email: Website: Hashtag: #Kaspersky The issuer is solely responsible for the content of this announcement. About Kaspersky Kaspersky is a global cybersecurity and digital privacy company founded in 1997. With over a billion devices protected to date from emerging cyberthreats and targeted attacks, Kaspersky's deep threat intelligence and security expertise is constantly transforming into innovative solutions and services to protect businesses, critical infrastructure, governments and consumers around the globe. The company's comprehensive security portfolio includes leading endpoint protection, specialized security products and services, as well as Cyber Immune solutions to fight sophisticated and evolving digital threats. We help over 200,000 corporate clients protect what matters most to them. Learn more at About SIS International Limited SiS International Limited is one of the largest distributors of IT solutions across Asian countries. With over 30 years in the distribution business, SiS has managed to build long-term and trusting relationships with vendors and channel partners. As an experienced distributor, SiS International Limited provides a wide variety of products and offers professional technical services. By delivering business solutions to our customers, we assist in successfully proliferating their businesses. Kaspersky
